Federico Stella

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Journal: Nature medicine

Published: August 26, 2026

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

Journal: The New England journal of medicine

Published: June 24, 2026

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

Journal: Science translational medicine

Published: February 04, 2026

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Journal: Bone marrow transplantation

Published: February 02, 2026

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Journal: Nature medicine

Published: December 18, 2025

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Journal: Blood advances

Published: October 20, 2025

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Journal: Transplantation and cellular therapy

Published: October 19, 2025

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Journal: Blood

Published: September 02, 2025

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Journal: Blood

Published: September 02, 2025

Outcomes of relapse after teclistamab therapy in multiple myeloma.

Outcomes of relapse after teclistamab therapy in multiple myeloma.

Journal: Blood cancer journal

Published: August 14, 2025

Showing 1-12 of 26

Last Updated: 09/26/2026